

Resource Summary Report

Generated by [RRID](#) on Sep 4, 2026

MDM2 (D1V2Z)

RRID:AB_2784534

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 86934, RRID:AB_2784534

Antibody Information

URL: http://antibodyregistry.org/AB_2784534

Proper Citation: Cell Signaling Technology Cat# 86934, RRID:AB_2784534

Target Antigen: MDM2

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IF-IC

Antibody Name: MDM2 (D1V2Z)

Description: This monoclonal targets MDM2

Target Organism: human

Clone ID: D1V2Z

Antibody ID: AB_2784534

Vendor: Cell Signaling Technology

Catalog Number: 86934

Record Creation Time: 20231110T032951+0000

Record Last Update: 20260830T013225+0000

Ratings and Alerts

No rating or validation information has been found for MDM2 (D1V2Z).

No alerts have been found for MDM2 (D1V2Z).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Vaubel RA, et al. (2026) Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts. *Neuro-oncology advances*, 8(1), vda259.

Marescal O, et al. (2025) 19S proteasome loss regulates mitotic spindle assembly through a ubiquitin-independent degradation mechanism. *Cell reports*, 44(8), 116041.

Vaubel RA, et al. (2025) Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(17), 3771.

Goerg A, et al. (2025) Mdm2 targeting via PROteolysis TARgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition. *BMC cancer*, 25(1), 978.

Puzio-Kuter AM, et al. (2025) Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. *Cancer discovery*, 15(6), 1159.

Zhang XL, et al. (2025) Designer polyQ fusion proteins sequester USP7/HDM2 for modulating P53 functionality. *iScience*, 28(3), 112025.

Yuan L, et al. (2025) Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degradator of the Nuclear Pore Complex. *Cancer discovery*, 15(12), 2505.

Indeglia A, et al. (2025) Targeted citrullination enables p53 binding to non-canonical sites. *Molecular cell*, 85(19), 3588.

Albert V, et al. (2024) HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice. *International journal of molecular sciences*, 25(13).

Tahara S, et al. (2024) Comparison of three-dimensional cell culture techniques of dedifferentiated liposarcoma and their integration with future research. *Frontiers in cell and developmental biology*, 12, 1362696.

Majc B, et al. (2024) Patient-derived tumor organoids mimic treatment-induced DNA damage response in glioblastoma. *iScience*, 27(9), 110604.

Futran AS, et al. (2024) Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activity. *iScience*, 27(5), 109693.

Cordova RA, et al. (2024) Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. *Science signaling*, 17(864), eadp1375.

Ku J, et al. (2024) Alternative polyadenylation determines the functional landscape of inverted Alu repeats. *Molecular cell*.

Qiu B, et al. (2024) Fatal COVID-19 pulmonary disease involves ferroptosis. *Nature communications*, 15(1), 3816.

Hsieh FS, et al. (2024) Plausible, robust biological oscillations through allelic buffering. *Cell systems*, 15(11), 1018.

Ming S, et al. (2024) Alphaherpesvirus manipulates retinoic acid metabolism for optimal replication. *iScience*, 27(7), 110144.

Tahara S, et al. (2023) Three dimensional models of dedifferentiated liposarcoma cell lines: scaffold-based and scaffold-free approaches. *Human cell*, 36(3), 1081.

Wu Z, et al. (2023) Coupled deglycosylation-ubiquitination cascade in regulating PD-1 degradation by MDM2. *Cell reports*, 42(7), 112693.

Carlock C, et al. (2023) PRL2 inhibition elevates PTEN protein and ameliorates progression of acute myeloid leukemia. *JCI insight*, 8(19).